Thursday, April 5, 2018

Nilotinib


 NILOTINIB
Nilotinib is a transduction inhibitor that targets BCR-ABL, c-kit and PDGF, for the potential treatment of various leukemias, including chronic myeloid leukemia (CML). Chronic myelogenous leukemia (CML) is caused by the BCR-ABL oncogene. Nilotinib inhibits the tyrosine kinase activity of the BCR-ABL protein.



Reference
Tripathi K.D.,” Essentials of Medical Pharmacology”, Jaypee Brothers Medical Publishers (P) LTD, New Delhi, Seventh Edition, Pg No. 870

No comments:

Post a Comment